UNSPSC 51411905: Fantofarone

This classification denotes an enzyme inhibitor and calcium channel blocker with the molecular formula C31H38N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier KU213XYO69, chemically known as 3,4-dimethoxy-n-methyl-n-(3-(4-((2-(1-methylethyl)-1-indolizinyl)sulfonyl)phenoxy)propyl)benzeneethanmine but generally known as fantofarone, which bears US NIH Compound Identifier 119349. European Medicines Agency schedules Fantofarone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07510MIG.

UNSPSC 51411905 Fantofarone, a Commodity code, covers emergency medications and pharmaceutical products that state and local governments procure for medical response, public health programs, and employee health plans. State and local buyers under this code include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across dozens of member jurisdictions. The work being solicited encompasses sealed-bid purchases of specific emergency life-support medications in measured quantities with strict expiration-date and delivery requirements, as well as strategic market-intelligence gathering and long-term manufacturer contracts for generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to state and local facilities.

Recent activity spans Florida, Texas, and Minnesota-led multistate purchasing. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem vials) for Tampa Fire Rescue, with a response deadline of April 8, 2026, an estimated contract value of $40,000, and a Small Local Business Enterprise set-aside with a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs operating outside traditional pharmacy benefit managers and group purchasing organizations, signaling strategic interest in alternative distribution models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products available through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026, a two-year initial term effective July 1, 2026, and evaluation weighted 75 percent on price competitiveness alongside manufacturing compliance, wholesaler relationships, and electronic data interchange capability.